Abnormal low expression of SFTPC promotes the proliferation of lung adenocarcinoma by enhancing PI3K/AKT/mTOR signaling transduction

Baile Zuo; Lin Wang; Xiaoyan Li; Xin Li; Jinping Wang; Yanlu Xiong; Jie Lei; Xi Zhang; Yifan Chen; Qiongwen Liu; Jinke Jiao; Mengru Sui; Jinhan Fan; Ningxue Wu; Zewen Song; Guoyin Li

doi:doi:10.18632/aging.205191

← Back

Research Paper Volume 15, Issue 21 pp 12451—12475

Abnormal low expression of SFTPC promotes the proliferation of lung adenocarcinoma by enhancing PI3K/AKT/mTOR signaling transduction

Figure 6. Tumor purity combined with SFTPC-related risk score to evaluate the prognosis of LUAD patients. (A) The immune and stromal scores of LUAD patients in the TCGA_LUAD cohort, grouping based on the risk score. (B) The tumor purity of LUAD patients in the TCGA_LUAD cohort, grouping based on the risk score. (C–H) Kaplan-Meier curves of the OS of LUAD patients in different subgroups from TCGA_LUAD (C, D), GSE72094 (E, F), and GSE41271 (G, H) cohorts.